| Periodo | Prezzo | Var. |
| 2026-05 | 41.03 USD | +0.00% |
| 2026-05 | 41.03 USD | +0.00% |
| 2026-05 | 41.03 USD | -0.07% |
| 2026-05 | 41.06 USD | +0.10% |
| 2026-05 | 41.02 USD | -0.02% |
| 2026-05 | 41.03 USD | +0.05% |
| 2026-05 | 41.01 USD | -0.27% |
| 2026-05 | 41.12 USD | +0.37% |
| 2026-05 | 40.97 USD | +0.00% |
| 2026-05 | 40.97 USD | +0.02% |
| 2026-05 | 40.96 USD | +0.02% |
| 2026-04 | 40.95 USD | +0.00% |
| 2026-04 | 40.95 USD | -0.10% |
| 2026-04 | 40.99 USD | — |
Apellis Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic compounds that inhibit the complement system to treat autoimmune and inflammatory diseases. Its key products include EMPAVELI, approved for paroxysmal nocturnal hemoglobinuria, cold agglutinin disease, C3 glomerulopathy, immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE, indicated for geographic atrophy secondary to age-related macular degeneration. The company targets complement-mediated rare diseases in ophthalmology, hematology, and nephrology through its C3 complement science platform. Apellis Pharmaceuticals Inc. maintains collaborations, such as with Swedish Orphan Biovitrum AB for pegcetacoplan development and commercialization, and with Beam Therapeutics Inc. for base editing technologies in complement-driven diseases. Founded in 2009 and headquartered in Waltham, Massachusetts, it plays a significant role in advancing targeted therapies for conditions with high unmet medical needs in the biopharmaceutical sector.